BioMed Research International / 2019 / Article / Tab 4

Research Article

Technical Verification and Assessment of Independent Validation of Biomarker Models for Endometriosis

Table 4

Levels of plasma biomarkers for endometriosis (all stages) versus controls.

BiomarkerPhase of cycleTechnical verification studyValidation study
ControlEndometriosisp-valueControlEndometriosisp-value

CA-125 (U/ml)All (no med)15.6119.2813.0020.00
(11.38-22.52)(13.11-31.76)(9.000- 16.00)(14.00- 29.75)

Menstrual19.4920.56NS16.0025.00NS
(12.39-27.42)(14.83-37.39)(13.00- 23.50)(13.00- 50.00)

Follicular11.9718.8111.0020.00
(9.859-16.13)(12.16-29.44)(8.000-17.00)(11.75- 27.50)

Luteal16.9919.09NS12.0019.00
(12.62-25.34)(13.07-30.30)(9.500- 13.00)(15.00- 25.00)

MedicationN/AN/AN/A9.00015.00
(5.000- 12.00)(9.750- 24.25)

VEGF (pg/ml)All (no med)41.4440.82NS404.6442.9NS
(27.49- 58.59)(28.52- 67.48)(296.5-545.1)(299.5-525.8)

Menstrual43.6944.57NS414.3478.8NS
(29.50- 54.13)(30.62- 68.32)(364.5-507.0)(366.7-548.9)

Follicular34.9040.16NS400.0424.0NS
(25.17- 47.24)(26.24- 61.08)(278.5-581.5)(254.4-521.2)

Luteal56.2238.05NS399.3425.4NS
(22.36-98.14)(27.12-76.66)(312.3-568.1)(322.3-512.2)

MedicationN/AN/AN/A368.7376.5NS
(217.2-490.4)(263.4-449.7)

Annexin VAll (no med)15.5112.62NS7.32210.16NS
(ng/ml)(11.41-20.56)(8.860-19.59)(3.568-49.06)(3.051-43.65)

Menstrual15.6916.05NS4.5196.031NS
(13.94-18.17)(9.640-22.31)(2.031-25.69)(2.387-26.19)

Follicular15.0612.67NS9.32011.39NS
(11.16-18.06)(6.565-19.73)(3.097-24.11)(3.280-45.55)

Luteal17.1311.95NS17.0510.40NS
(8.490-24.31)(8.610-18.25)(3.881-63.47)(3.364-60.85)

MedicationN/AN/AN/A17.414.977
(4.489-57.69)(2.523-11.56)

sICAM-1 (ng/ml)All (no med)154.8147.7NS209.5201.0NS
(137.4-182.1)(130.9-195.5)(183.3- 236.2)(171.0-226.2)

Menstrual176.0172.4NS195.7201.0NS
(135.0-246.9)(130.9-298.0)(186.0-230.2)(167.8-226.7)

Follicular149.0153.2NS207.9210.9NS
(130.7-170.8)(129.4-204.2)(171.0-228.9)(168.3-237.4)

Luteal155.7144.3NS227.4186.8NS
(134.1-177.1)(130.7-164.6)(189.1-241.2)(171.8-216.3)

MedicationN/AN/AN/A227.4182.3
(197.7-260.3)(163.8-204.7)

GlycodelinAll (no med)29.0634.76NS3.2375.612
(ng/ml)(11.90-47.50)(16.20-85.41)(1.254-11.30)(2.250-17.83)

Menstrual45.68109.7NS7.24219.68NS
(37.62-109.1)(39.79-190.7)(2.312-19.86)(10.46-40.30)

Follicular12.8717.42NS1.5735.191NS
(9.850-23.80)(10.19-34.30)(0.9660-7.578)(2.126-9.351)

Luteal31.1343.26NS5.0263.669NS
(11.91-54.83)(20.29-99.28)(1.513-11.30)(1.772-8.920)

MedicationN/AN/AN/A0.95022.535NS
(0.6382-3.436)(1.032-4.221)

Data are presented as the median and interquartile range. Mann-Whitney test was performed for all phases combined, while Kruskal-Wallis with post-hoc Dunn’s analysis was done when biomarkers were analyzed according to cycle phase. No med = no medication. NS = not significant. N/A indicates that there was no medication cohort included in the technical verification study

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.